{"id":"insulin-lispro-mix25","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a premixed insulin formulation containing 25% insulin lispro (rapid-acting) and 75% insulin lispro protamine suspension (intermediate-acting). The rapid-acting component provides quick postprandial glucose control, while the intermediate-acting component provides basal coverage. Together, they mimic physiologic insulin secretion patterns by activating insulin receptors on muscle, fat, and liver cells to promote glucose uptake and storage.","oneSentence":"Insulin Lispro Mix25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:20.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05373186","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT04023344","phase":"PHASE3","title":"Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":210},{"nctId":"NCT03606018","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-04-12","conditions":"Clamp Study","enrollment":48},{"nctId":"NCT02915250","phase":"PHASE1","title":"A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2016-10","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT02514850","phase":"PHASE1","title":"A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02514954","phase":"PHASE1","title":"Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 1 Diabetes Mellitus","enrollment":28},{"nctId":"NCT01773473","phase":"PHASE4","title":"Comparison of Insulin Mix25 Versus Mix50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":403},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01147627","phase":"NA","title":"Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2, Newly Diagnosed","enrollment":416},{"nctId":"NCT00551356","phase":"PHASE3","title":"Lispro Mix 25 vs. Glargine in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-11","conditions":"Diabetes Mellitus Type 2","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY275585-75"],"phase":"marketed","status":"active","brandName":"Insulin Lispro Mix25","genericName":"Insulin Lispro Mix25","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Lispro Mix25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}